BRIEF-Rallybio Corporation And Avenzo Therapeutics Announce Merger Agreement To Advance Next-Generation Oncology Therapies And $215 Million Concurrent Private Placement

Rallybio

Rallybio

RLYB

0.00

June 1 (Reuters) - Rallybio Corp RLYB.O:

  • RALLYBIO CORPORATION AND AVENZO THERAPEUTICS ANNOUNCE MERGER AGREEMENT TO ADVANCE NEXT-GENERATION ONCOLOGY THERAPIES AND $215 MILLION CONCURRENT PRIVATE PLACEMENT

  • RALLYBIO - COMBINED COMPANY TO OPERATE AS AVENZO THERAPEUTICS, TRADE AS AVZO ON NASDAQ

  • RALLYBIO - PRE-DEAL RALLYBIO EQUITYHOLDERS TO OWN 2.8%, AVENZO EQUITYHOLDERS 97.2% OF COMBINED COMPANY

  • RALLYBIO - ATHENA COUNTOURIOTIS TO LEAD COMBINED COMPANY AS CHAIR, PRESIDENT AND CEO

Source text: ID:nBw8PBsQHa

Further company coverage: RLYB.O


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.